Myrtho Branch
Child & Adolescent Psychiatry · Orlando, FLNPI 1386675205
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 189 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,554, 2.7 times the $581 reported in 2019.
Across 189 payments — averaging $26.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$895
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$685
- Johnson & Johnson$613
- E.r. Squibb & Sons, L.L.C.$410
- Ironshore Pharmaceuticals Inc.$303
- Axsome Therapeutics, Inc.$233
- plus $2K from 19 others
What the payments were for
- Food & beverage$4,96098%
- Education$912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 32 | $895 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $685 |
| Johnson & Johnson | 17 | $613 |
| E.r. Squibb & Sons, L.L.C. | 10 | $410 |
| Ironshore Pharmaceuticals Inc. | 11 | $303 |
| Axsome Therapeutics, Inc. | 5 | $233 |
| AbbVie | 13 | $226 |
| Neurocrine Biosciences, Inc. | 8 | $209 |
| Tris Pharma Inc | 10 | $204 |
| Corium, LLC | 11 | $193 |
| Supernus Pharmaceuticals, Inc. | 10 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $148 |
| Neuronetics, Inc. | 2 | $147 |
| Teva Pharmaceuticals USA, Inc. | 2 | $137 |
| Alkermes, Inc. | 5 | $117 |
| Collegium Pharmaceutical, Inc. | 4 | $79 |
| Sunovion Pharmaceuticals Inc. | 5 | $76 |
| Adlon Therapeutics L.p. | 2 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $40 |
| Neos Therapeutics, LP | 2 | $37 |
| Shire North American Group Inc | 2 | $32 |
| Noven Therapeutics, LLC | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Bausch Health US, LLC | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$330
- SPRAVATO$318
- COBENFY$244
- CAPLYTA$235
- NEUROSTAR TMS THERAPY$127
- REXULTI$122
- Auvelity$116
- AUSTEDO$110
- Jornay PM 20mg capsules (Bottle of 100)$110
- ABILIFY ASIMTUFII$107
How this compares
$5,051 in reported general payments places this provider in the 85th percentile of 206 child & adolescent psychiatry providers in Florida.
See all child & adolescent psychiatry providers in Florida →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 14 | $14,448 |
| AbilifyAripiprazole | 12 | $7,823 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,313 |
| Paliperidone ErPaliperidone | 39 | $5,463 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 34 | $2,440 |
| Clozapine | 34 | $1,882 |
| Clonazepam | 105 | $1,589 |
| Aripiprazole | 27 | $1,571 |
| Perphenazine | 15 | $1,386 |
| Duloxetine Hcl | 50 | $667 |
| Bupropion XlBupropion Hcl | 17 | $563 |
| Trazodone Hcl | 29 | $407 |
| Haloperidol | 13 | $365 |
| Divalproex Sodium | 35 | $351 |
| Risperidone | 23 | $321 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $895 | $14,44814 claims |
| E.r. Squibb & Sons, L.L.C.Abilify | $410 | $7,82312 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $148 | $6,31313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 206 child & adolescent psychiatry providers in Florida.
Other child & adolescent psychiatry in Orlando
- Bhaskar RajuOrlando$11K
- Craig KuninsGulfport$265K
- Elias SarkisGainesville$169K
- Jeffrey AlvaroSt Petersburg$87K
- Rosa Negron MunozLakeland$39K
- Sean HoranMiami$17K
- Rachel AgustinesLargo$16K
- Carlos BorgeSarasota$15K
- Justin SpoonerPonte Vedra Beach$12K
- Americo PadillaMiami$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.